PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tadalafil. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

21 hits

Bibliografisk träff 2013-02-01

Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.

Gur S, Kadowitz PJ, Gokce A, Sikka SC, Lokman U, Hellstrom WJ.

Curr Drug Metab · review; journal article · DOI 10.2174/1389200211314020014

Bibliografisk träff 2013-01-24

Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.

Giuliano F, Oelke M, Jungwirth A, Hatzimouratidis K, Watts S, Cox D, Viktrup L.

J Sex Med · multicenter study; randomized controlled trial; journal article · DOI 10.1111/jsm.12039

Bibliografisk träff 2013-01-24

Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus.

Hamidi Madani A, Asadolahzade A, Mokhtari G, Shahrokhi Damavand R, Farzan A, Esmaeili S.

J Sex Med · randomized controlled trial; journal article · DOI 10.1111/jsm.12047

Bibliografisk träff 2013-01-01

Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.

Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.

J Urol · multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.juro.2012.11.025

Bibliografisk träff 2012-12-20

Re: combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-responders with severe and intermediate testosterone deficiency.

Seftel AD.

J Urol · comment; journal article · DOI 10.1016/j.juro.2012.11.039

Bibliografisk träff 2012-12-12

Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.

Waxman A, Chen SY, Boulanger L, Watson JA, Golden G.

J Med Econ · research support, non-u.s. gov't; journal article · DOI 10.3111/13696998.2012.756399

Bibliografisk träff 2012-12-05

Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.

Weiss J, Theile D, Spalwisz A, Burhenne J, Riedel KD, Haefeli WE.

Biochem Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2012.11.020

Bibliografisk träff 2012-11-28

Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.

Yamaguchi O.

Int J Urol · review; journal article · DOI 10.1111/iju.12008

Bibliografisk träff 2012-11-01

The selective phosphodiesterase-5 inhibitor tadalafil induces microvascular and metabolic effects in type 2 diabetic postmenopausal females.

Murdolo G, Sjöstrand M, Strindberg L, Lönnroth P, Jansson PA.

J Clin Endocrinol Metab · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1210/jc.2012-1830

Bibliografisk träff 2012-10-17

Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.

Hood B, Andersson KE.

Int J Urol · review-article; review; journal article · DOI 10.1111/j.1442-2042.2012.03196.x

Bibliografisk träff 2012-10-08

Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia.

Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Keys T, Peyton C, Yamaguchi O, Andersson KE.

J Urol · journal article · DOI 10.1016/j.juro.2012.07.141

Bibliografisk träff 2012-10-02

Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.

Cahill KB, Quade JH, Carleton KL, Cote RH.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m112.389189

Bibliografisk träff 2012-09-19

Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.

Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M.

Prostate · research support, non-u.s. gov't; journal article · DOI 10.1002/pros.22584

Bibliografisk träff 2012-09-13

Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency.

Kim JW, Oh MM, Park MG, Park JY, Bae JH, Kim JJ, Moon DG.

Int J Impot Res · journal article · DOI 10.1038/ijir.2012.32

Bibliografisk träff 2012-09-01

Optical coherence tomography in tadalafil-associated retinal toxicity.

Coscas F, Coscas G, Zucchiatti I, Bandello F, Soubrane G, Souïed E.

Eur J Ophthalmol · journal article; case reports · DOI 10.5301/ejo.5000127

Bibliografisk träff 2012-07-07

Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.

García-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Sallés J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, García-Osta A.

Neuropharmacology · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2012.06.052

Bibliografisk träff 2012-06-27

Selective imaging of active pharmaceutical ingredients in powdered blends with common excipients utilizing two-photon excited ultraviolet-fluorescence and ultraviolet-second order nonlinear optical imaging of chiral crystals.

Toth SJ, Madden JT, Taylor LS, Marsac P, Simpson GJ.

Anal Chem · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/ac300917t

Bibliografisk träff 2012-03-24

Analysis of counterfeit Cialis® tablets using Raman microscopy and multivariate curve resolution.

Kwok K, Taylor LS.

J Pharm Biomed Anal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jpba.2012.03.026

Bibliografisk träff 2011-09-22

Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry.

Ortiz RS, Mariotti KC, Schwab NV, Sabin GP, Rocha WF, de Castro EV, Limberger RP, Mayorga P, Bueno MI, Romão W.

J Pharm Biomed Anal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jpba.2011.09.005

Bibliografisk träff 2011-06-15

[Serous central chorioretinopathy and tadalafil: a case report].

Nadeau S, Nguyen F, Guigou S.

J Fr Ophtalmol · journal article; english abstract; case reports · DOI 10.1016/j.jfo.2011.02.016

Bibliografisk träff 2010-11-05

The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups.

Baek SB, Bahn G, Moon SJ, Lee J, Kim KH, Ko IG, Kim SE, Sung YH, Kim BK, Kim TS, Kim CJ, Shin MS.

Neurosci Lett · journal article · DOI 10.1016/j.neulet.2010.10.074